A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Exelixis, Inc
Start Date
September 1, 2013
End Date
August 31, 2016
Administered By
Duke Cancer Institute
Awarded By
Exelixis, Inc
Start Date
September 1, 2013
End Date
August 31, 2016